Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) is unable to file, without unreasonable effort or expense, our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”) by the prescribed due date. We will require additional time to furnish information in connection with the completion of the first audit of annual financial statements by our registered independent accounting firm which we retained in September 2024. We anticipate filing the Form 10-K on or before the 15th calendar day following the prescribed due date. PART IV - OTHER INFORMATION (1) Name and telephone number of the person to contact in regard to this notification: Yasushi Nagasaki (310) 214-0065 (Name) (Area Code) (Telephone number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s): ☒ Yes ☐ No (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof: ☒ Yes ☐ No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. 2 Emmaus Life Sciences, Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 1, 2025 /s/ Yasushi Nagasaki Yasushi Nagasaki Chief Financial Officer INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) is unable without unreasonable effort or expense to file our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) by the prescribed due date. Our newly appointed independent registered public accounting firm was engaged on October 22, 2024, and we require additional time to fully acquaint them with our financial accounting practices and procedures in connection with their review of our quarterly financials. We anticipate filing the Form 10-Q on or before November 19, 2024, the fifth calendar day following the prescribed due date

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) is unable to file, without unreasonable effort or expense, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Form 10-Q”) by the prescribed due date. We must first complete and file our delinquent Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 before we can complete and file our Quarterly Report. We anticipate filing the Form 10-Q on or before August 19, 2024, the fifth calendar day following the prescribed due date. PART IV - OTHER INFORMATION (1) Name and telephone number of the person to contact in regard to this notification: Yasushi Nagasaki (310) 214-0065 (Name) (Area Code) (Telephone number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s): ☐ Yes ☒ No Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof: ☒ Yes ☐ No If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. Emmaus Life Sciences, Inc. (Name of Registrant as Specified in Charter) has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2024 /s/ Yasushi Nagasaki Yasushi Nagasaki Chief Financial Officer INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” the “company” or “Emmaus”) is unable to file, without unreasonable effort or expense, our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Form 10-K”). Additional time is needed for the Company’s independent registered public accounting firm to complete its review of our accounting for the disposition of our equity interest in a variable interest entity, or VIE, and its impact on loans receivable from the VIE. We anticipate filing the Form 10-K on or before April 15, 2024

Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) is unable to file, without unreasonable effort or expense, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) by the prescribed due date. We require additional time to first complete and file our delinquent Quarterly Reports on Form 10-Q for 2020 and to complete the Form 10-Q to ensure the accuracy of the filings. We do not anticipate filing the Form 10-Q on or by May 24, 2021, the fifth calendar day following the prescribed due date

The Company is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ending December 31, 2020 (the “Form 10-K”). Additional time is needed for the Company’s independent registered public accounting firm to complete its review of the financial statements included in the Form 10-K and for the Company to provide additional information to its accounting firm in order to ensure a complete, accurate Annual Report. The Company anticipates filing its Form 10-K on or by April 15, 2021